A5320: Viral Hepatitis C Infection Long-term Cohort Study (V-HICS)

Study Location:

Baltimore

Topic:

Hepatitis and HIV

Clinicaltrials.gov Link:

N/A

IRB#:

NA_00092078

Coordinator:

Ilene Wiggins, RN (Baltimore)

Anna Wimpelberg (Washington)

Enrollment:

Closed

Trial Period:

Ongoing

A5320/V-HICS is an observational, prospective, long-term follow-up study in hepatitis C virus (HCV) monoinfected and HCV/HIV-1 coinfected participants who received direct-acting antiviral (DAA) therapy for HCV infection.

Men and women ≥ 18 years old, HCV/HIV-1 coinfected who failed HCV therapy any time after HCV/DAA treatment discontinuation (non-SVR); or HCV monoinfected who failed HCV therapy any time after HCV/DAA treatment discontinuation (non-SVR); or HCV/HIV-1 coinfected participants who achieved a SVR at least 12 weeks after treatment completion; or HCV monoinfected participants who achieved a SVR as at least 12 weeks after treatment completion.

Anna Wimpelberg (Washington)
202-797-3589
awimpelberg@whitman-walker.org


​Ilene Wiggins, RN (Baltimore)
410-614-2766
iwiggin1@jhmi.edu

Categories

Location
Topic

Clinical Trials

A5320: Viral Hepatitis C Infection Long-term Cohort Study...

A5320/V-HICS is an observational, prospective, long-term follow-up study in hepatitis C virus (HCV) monoinfected and HCV/HIV-1...

Read More

A5128: Consent for Use of Stored Patient Specimens for...

The purpose of this study is to obtain informed consent to use stored human biological materials (HBM) (e.g., blood and other...

Read More

P1060:  Phase II, parallel, randomized, clinical trials...

A single dose of nevirapine (SD NVP) given to an HIV infected pregnant woman followed by a single dose to her infant has been...

Read More

NWCS 414, Evaluation of a Serum Biosignature for Identifying...

We will address our hypothesis using a case-control study design. We plan to leverage the existing biorepository of...

Read More

A5314: Effect of LDMTX on Inflammation in HIV-infected...

A5314 is a phase II randomized, double-blind, placebo-controlled 36-week trial that will examine the safety and efficacy of...

Read More